TALL-104; T Cell Leukemia (ALL); Human (Homo sapiens) Item ID: ATCCRL11386
| Permits and Restrictions |
View Permits |
|---|---|
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | T lymphoblast |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | acute lymphoblastic leukemia |
| Age | 2 years |
| Gender | male |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype | 46, XY; t(11;14)(p13;q11) |
|---|---|
| Derivation | The TALL-104 line was established from the peripheral blood of a child in relapse with T-ALL. |
| Clinical Data | male peripheral blood of a child in relapse with T-ALL |
| Antigen Expression | CD2 +; CD3 +; CD7 +; CD8 +; CD56 +; CD4 -; CD16 - |
| Receptor Expression | T cell antigen receptor alpha/beta (TCR), expressed interleukin 2 (IL-2), expressed interleukin 2 (IL-2); T cell antigen receptor alpha/beta (TCR) |
| Genes Expressed | interferon gamma (IFN gamma); tumor necrosis factor alpha (TNF alpha); granulocyte monocyte colony stimulating factor (GM-CSF) |
| Cellular Products | interferon gamma (IFN gamma); tumor necrosis factor alpha (TNF alpha); granulocyte monocyte colony stimulating factor (GM-CSF) |
| Comments | The TALL-104 line was established from the peripheral blood of a child in relapse with T-ALL. The cells are highly cytotoxic and are capable of tumor destruction in vivo and in vitro. IL-2 is required from optimal growth and long term cultivation, but the cells can be grown for short periods without IL-2 (growth will be slower). The cells are positive for the alpha/beta TCR and negative for gamma/delta TCR. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. ATCC 30-2005. To make the complete growth medium, add the following components to the base medium: 50 to 100 units/ml recombinant human IL-2; 2.5 microgram/ml human albumin; 0.5 microgram/ml D-mannitol; fetal bovine serum to a final concentration of 20%. |
|---|---|
| Subculturing | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at least 8 X 105 cells/mL. Note: IL-2 rapidly loses its potency in medium, it is important that fresh IL-2 be used. Interval: Maintain between 4 X 105 and 1 X 106 cells/mL. Medium Renewal: Add medium as cell density increases |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 50% fetal bovine serum, and 10% DMSO. Freeze at a cell density of at least 15 X 10(6) cells/ml Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C Growth Conditions: Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium. ATCC recommends using the highest quality IL-2 available. |
| STR Profile | Amelogenin: X,Y CSF1PO: 10,11 D13S317: 9,12 D16S539: 12 D5S818: 12,13 D7S820: 7,13 THO1: 7,9 TPOX: 8,9 vWA: 14,18 |
|---|
| Name of Depositor | Wistar Institute |
|---|---|
| U.S. Patent Number | 5,272,082 |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| References |
Santoli D, et al. Cytotoxic T-ALL cell lines and uses therefor. US Patent 5,272,082 dated Dec 21 1993 O'Connor R, et al. Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 77: 1534-1545, 1991. PubMed: 1706955 Cesano A, et al. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 77: 2463-2474, 1991. PubMed: 2039829 |